Table 1 Clinical characteristics of patients with type 2 diabetes and nephropathy as total cohort and grouped according to the median of MRP8/14
Characteristics | ALL (n= 43) | < MRP8/14 median (n= 22) | > MRP8/14 median (n= 21) |
|---|---|---|---|
Age (years) | 66.5 ± 12.2 | 65.2 ± 13.6 | 67.3 ± 12.0 |
Gender (% men) | 58.1 | 68.2 | 47.6 |
BMI (kg/m2) | 31.2 ± 5.9 | 29.8 ± 3.9 | 32.3 ± 7.6 |
Waist circumference (cm) | 110.7 ± 15.3 | 107.1 ± 10.4 | 114.4 ± 19.1 |
Smoking (%) | 6.9 | 13.6 | 0.0 |
Glycemia (mmol/l) | 6.55 ± 1.95 | 6.64 ± 1.46 | 6.43 ± 1.86 |
Hba1c (%) | 6.7 ± 0.8 | 6.7 ± 0.8 | 6.7 ± 0.7 |
Cholesterol (mmol/l) | |||
Total | 180.2 ± 37.6 | 171.2 ± 33.6 | 185.1 ± 38.5 |
HDL | 49.1 ± 13.6 | 46.4 ± 9.8 | 51.2 ± 13.2 |
LDL | 100.2 ± 31.6 | 96.9 ± 28.9 | 104.1 ± 35.6 |
Triglyceridemia (mmol/l) | 174.9 ± 113.2 | 175.6 ± 94.8 | 146.1 ± 88.7 |
eGFR (ml/min/1.73 m2) | 61.3 ± 36.1 | 66.5 ± 30.0 | 55.1 ± 44.8 |
Protein-creatinine ratio (log) | -0.76 ± 0.54 | -0.96 ± 0.46 | -0.51 ± 0.52 ** |
Insulin therapy (%) | 32 | 17 | 50 * |
RAS-Inhibition (%) | 86 | 91 | 85 |
Statin therapy (%) | 45 | 57 | 35 |
Cardiovascular | |||
24 h systolic BP (mmHg) | 135.6 ± 11.5 | 134.1 ± 11.6 | 138.3 ± 11.4 |
24 h diastolic BP (mmHg) | 71.8 ± 10.9 | 72.6 ± 11.8 | 68.4 ± 10.0 |
24 h Pulse pressure (mmHg) | 63.8 ± 8.4 | 62.5 ± 7.7 | 66.5 ± 8.5 |
aPWV | 11.5 ± 3.1 | 11.7 ± 3.3 | 11.4 ± 2.9 |
CRAE (μm) | 169.1 ± 16.0 | 162.7 ± 14.9 | 178.3 ± 14.1 ** |
CRVE (μm) | 219.8 ± 22.3 | 217.4 ± 26.7 | 221.3 ± 19.2 |
AVR | 0.818 ± 0.085 | 0.796 ± 0.077 | 0.856 ± 0.082 * |
Inflammation and transmigration | |||
IL-6 (pg/ml) | 1.01 ± 1.09 | 0.59 ± 0.31 | 1.70 ± 1.52 * |
TNF-α (pg/ml) | 6.95 ± 4.52 | 5.05 ± 3.62 | 9.10 ± 5.27 * |
CRP (mg/dl) | 9.5 ± 13.2 | 5.3 ± 6.5 | 15.5 ± 19.1 |
MRP8/14 (μg/ml) | 8.53 ± 6.92 | 3.98 ± 1.04 | 14.08 ± 7.73 *** |